These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1342 related items for PubMed ID: 31189517

  • 1. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, Pratley R, Sathyapalan T, Desouza C, PIONEER 5 Investigators.
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [Abstract] [Full Text] [Related]

  • 2. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ, PIONEER 4 investigators.
    Lancet; 2019 Jul 06; 394(10192):39-50. PubMed ID: 31186120
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB, PIONEER 7 investigators.
    Lancet Diabetes Endocrinol; 2019 Jul 06; 7(7):528-539. PubMed ID: 31189520
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
    Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, Søndergaard AL, Tankova TI, Tentolouris N, Buse JB.
    Lancet Diabetes Endocrinol; 2021 Sep 06; 9(9):563-574. PubMed ID: 34293304
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F.
    Lancet Diabetes Endocrinol; 2017 May 06; 5(5):341-354. PubMed ID: 28385659
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC.
    Lancet Diabetes Endocrinol; 2017 Apr 06; 5(4):251-260. PubMed ID: 28110911
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.
    Wang W, Bain SC, Bian F, Chen R, Gabery S, Huang S, Jensen TB, Luo B, Yuan G, Ning G, PIONEER 11 investigators.
    Diabetologia; 2024 Sep 06; 67(9):1783-1799. PubMed ID: 38985162
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
    Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, Pedersen SD, Buse JB.
    Lancet; 2023 Aug 26; 402(10403):693-704. PubMed ID: 37385279
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH.
    Lancet Diabetes Endocrinol; 2017 May 26; 5(5):355-366. PubMed ID: 28344112
    [Abstract] [Full Text] [Related]

  • 10. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
    Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, Seino Y, PIONEER 9 investigators.
    Lancet Diabetes Endocrinol; 2020 May 26; 8(5):377-391. PubMed ID: 32333875
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, Thielke D, Viljoen A, McCrimmon RJ.
    Lancet Diabetes Endocrinol; 2019 Nov 26; 7(11):834-844. PubMed ID: 31540867
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.
    Ji L, Agesen RM, Bain SC, Fu F, Gabery S, Geng J, Li Y, Lu Y, Luo B, Pang W, Tao Y, PIONEER 12 investigators.
    Diabetologia; 2024 Sep 26; 67(9):1800-1816. PubMed ID: 38985161
    [Abstract] [Full Text] [Related]

  • 13. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A, SUSTAIN 7 investigators.
    Lancet Diabetes Endocrinol; 2018 Apr 26; 6(4):275-286. PubMed ID: 29397376
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
    Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, Inagaki N, PIONEER 10 Investigators.
    Lancet Diabetes Endocrinol; 2020 May 26; 8(5):392-406. PubMed ID: 32333876
    [Abstract] [Full Text] [Related]

  • 15. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z.
    Lancet Diabetes Endocrinol; 2022 Jun 26; 10(6):418-429. PubMed ID: 35468322
    [Abstract] [Full Text] [Related]

  • 16. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T.
    Lancet; 2023 Aug 12; 402(10401):529-544. PubMed ID: 37385280
    [Abstract] [Full Text] [Related]

  • 17. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A.
    Lancet Diabetes Endocrinol; 2019 May 12; 7(5):356-367. PubMed ID: 30833170
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
    Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M.
    Lancet; 2023 Aug 26; 402(10403):720-730. PubMed ID: 37364590
    [Abstract] [Full Text] [Related]

  • 19. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
    Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S, STEP 6 investigators.
    Lancet Diabetes Endocrinol; 2022 Mar 26; 10(3):193-206. PubMed ID: 35131037
    [Abstract] [Full Text] [Related]

  • 20. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT, OASIS 1 Investigators.
    Lancet; 2023 Aug 26; 402(10403):705-719. PubMed ID: 37385278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.